Atrium Therapeutics
Targets genetic drivers of rare cardiomyopathies with tissue-directed siRNA medicines.
Something off on this page? Send us feedback.
Profile
Develops targeted, non-viral siRNA medicines for rare genetic cardiomyopathies. Its narrow pipeline includes ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy.
Develops targeted, non-viral siRNA medicines for rare genetic cardiomyopathies. ATR 1072 targets PRKAG2 syndrome, while ATR 1086 targets PLN cardiomyopathy; additional targets remain at the research stage.
Built around a delivery platform that pairs tissue-selective antibodies or other delivery ligands with oligonucleotides, the pipeline seeks to reach heart tissue and address genetic drivers rather than symptoms. The company was separated from Avidity and began Nasdaq trading in 2026.
Near-term execution depends on the planned clinical study of ATR 1072, progress toward an IND for ATR 1086, and continued development of cardiac-tissue delivery.
Company facts
Key statistics
Year to date −7.6% · Average volume (30d) 142.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Aug 6, 2026 | H.C. Wainwright | Initiate | Buy | $25 | |
| Jun 18, 2026 | Cantor Fitzgerald | Target | $25 | ||
| May 15, 2026 | Leerink Partners | Target | $25 | ||
| Oct 29, 2025 | TD Cowen | Downgrade | Buy | Hold | |
| Oct 28, 2025 | RBC Capital | Downgrade | Outperform | Sector Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$1.42 | −$1.18 | +16.9% | $666.7K | $3.0M | +350.6% | +4.14% |
| May 14, 2026Q1 FY26 | −$1.05 | −$0.97 | +7.6% | $2.0M | $19.6M | +881.8% | −0.30% |
| Feb 26, 2026Q4 FY25 | −$1.24 | −$0.61 | +50.8% | $2.0M | $2.1M | +6.0% | — |
Financial highlights
| 3 quarters | — | — | — | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $859.0K | $19.6M | $3.0M | |
| Gross profit | — | — | — | $859.0K | $19.5M | $2.7M | |
| Operating income | — | — | — | −$48.0M | −$17.3M | −$22.6M | |
| Net income | — | — | — | −$48.1M | −$16.6M | −$20.2M | |
| Diluted EPS | — | — | — | −$1.70 | −$0.97 | −$1.18 | |
| Gross margin | — | — | — | 100.0% | 99.2% | 88.6% | |
| Operating margin | — | — | — | -5,592.0% | -88.0% | -752.9% |
Balance sheet, Jun 30, 2026Cash & short-term investments $264.2M · Total debt $1.7M · Total assets $280.5M · Shareholders' equity $214.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 17.11M · Float 15.72M · 91.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.94M | 8.30% | 13G | Nov 14, 2024 |
| Wellington Group Holdings LLP | 7.03M | 5.97% | 13G | Nov 8, 2024 |
| Sessa Capital Im, L.P. | 1.50M | 8.77% | 13F | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.47M | 8.61% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 1.45M | 8.46% | 13F | Aug 7, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Tenaya Therapeutics
Gene therapies targeting inherited cardiomyopathies
- Lexeo Therapeutics
AAV gene therapies for genetic cardiomyopathies
- Alnylam Pharmaceuticals
Approved RNAi medicine for ATTR cardiomyopathy
- Rocket Pharmaceuticals
AAV therapies across inherited cardiomyopathy subtypes
- BridgeBio Pharma
Approved medicine for transthyretin amyloid cardiomyopathy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Atrium Therapeutics | $13.64 | +0.07% | $233.3M | — | — | 9.9 | — |
| Tenaya Therapeutics | $0.6956 | +0.40% | $149.8M | — | — | 112.2 | — |
| Lexeo Therapeutics | $4.77 | −1.95% | $381.6M | — | — | — | — |
| Alnylam Pharmaceuticals | $240.00 | +1.22% | $31.73B | 40.1 | 26.7 | 6.6 | +66.9% |
| Rocket Pharmaceuticals | $3.82 | −0.91% | $421.5M | — | — | — | — |
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| Median | 40.1 | 26.7 | 21.7 | +93.6% |